Oncology ImagingArchives
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
Oncology Imaging 7 min.
Over the past two decades, HER2-targeted therapy has dramatically improved outcomes in advanced HER2-positive breast cancer [1, 2–3]. Trastuzumab combined with chemotherapy was the initial backbone, and the landmark phase III CLEOPATRA trial established that adding pertuzumab to first-line trastuzumab...
Adaptive ensemble learning for prostate cancer classification on multi-modal MRI: reducing unnecessary biopsies
Oncology Imaging 5 min.
Accurate diagnosis of prostate cancer using MRI remains challenging due to variable imaging presentations and differences in reader experience [1, 2]. Radiologists often struggle to maintain interpretation consistency, leading to substantial interobserver variability and suboptimal specificity in lesion...
Incidence and Resource Burden for the Management of CT-detected Ground-Glass Opacities at a Tertiary Lung Cancer Service in the United Kingdom
Oncology Imaging 1 min.
The increased use of CT for lung cancer screening has significantly raised awareness of pure ground-glass opacity (pGGO) lesions. GGOs pose diagnostic challenges, ranging from benign findings to invasive adenocarcinomas. We aim to evaluate the incidence of pGGOs identified on CT at a tertiary UK lung...
Prostate cancer with incidental thoracic splenosis: a diagnostic challenge unveiled by 18 F-PSMA PET/CT imaging
Oncology Imaging 3 min.
Thoracic splenosis is a rare, acquired anomaly in which splenic cells are autotransplanted into the thoracic cavity after thoracoabdominal trauma or surgery. Overall, splenosis is relatively common, occurring in approximately 58% to 65% of patients after splenic trauma. In these cases, the splenic tissue...
Multiparametric MRI-based habitat analysis integrating deep learning and radiomics for predicting preoperative Ki-67 expression level in breast cancer
Oncology Imaging 4 min.
Breast cancer(BC) is the most common and malignant tumor in women worldwide [1]. Accurate risk stratification and timely treatment are essential for improving prognosis. The routinely used immunohistochemistry (IHC) includes Progesterone Receptor(PR), Estrogen Receptor(ER), Human Epidermal Growth Factor...
